



## 06/10/2009 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Iris MEIRI-BENDEK et al

Confirmation No.: 9083

Application No.: 10/576,240

Attorney Docket No.: 7640-X06-056

Filed: April 28, 2006

Group Art Unit: 1761

For: HUMAN BREAST MILK LIPID MIMETIC AS DIETARY SUPPLEMENT

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents Alexandria, VA 22313

Sir:

In accordance with the duty of disclosure provisions of C.F.R. § 1.56, there is hereby provided certain information, which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

A revised Forms PTO/SB/08a and PTO/SB/08b listing all patents, publications, applications, or other information submitted for consideration is enclosed.

No admission is made that the information cited in this Statement is, or is considered to be prior art, material to patentability nor a representation that a search has been made.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or certification is required.

Respectfully submitted,

305-830-2600 (telephone)

Dated: 19 JAN 2007

ROPE

Paul D. Bianco (Reg. No. 43,500) Attorney for Applicant Fleit, Kain, Gibbons, Gutman, Bongini & Bianco P.L. 21355 East Dixie Highway Suite 115 Miami, Florida 33180 PATENT

Attorney Docket No.: 7640-X06-056

(پېر N 19 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Iris MEIRI-BENDEK, Gai BEN DROR, Hala LAOUZ, Dov YAAKOBI, Zohar

BAR-ON and Avidor SHULMAN

Serial No:

Confirmation No.

10/576,240

Filed:

April 28, 2006

Title:

9083

HUMAN BREAST MILK LIPID MIMETIC AS DIETARY SUPPLEMENT

## CERTIFICATE OF EXPRESS MAILING

**PATENTS** 

EXPRESS "Express Mail" Mailing Label number EV 820314265 US

Date of Deposit January 19, 2007

I hereby certify that the attached paper(s) or fee(s) is/are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Estefounabellumole

(Signature of person mailing paper or fee

ESTEFANIA BELAUNDE

(Typed or printed name of person mailing paper or fee)

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Index he Paperwork Reduction Act of 1995, no persons are required to respond

/ INFORMATION DISCLOSURE STATEMENT BY APPLICANT

R R TA TA

Sheet 1

(Use as many sheets as necessary)

Examiner	1 62			DOCUMENTS	T = 10.1
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (or Innown)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 3,542,560	11-24-1970	Tomarelli	
	AB	US- 4,876,107	10-24-1989	King et al.	
	AC	US- 5,658,768	08-19-1997	Quinlan	
	AD	US- 5,709,888	01-20-1998	Gil et al.	
		US-			

		FOREIG	N PATENT DOCU	MENTS		$\neg$
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
	AE	EP 0 209 327	01-21-1987	Unilever PLC, Unilever NV		
	AF	EP 0 495 456	07-22-1992	Daikin Industries, Limited		
	AG	EP 0 882 797	12-09-1998	Unilever N.V., Unilever PLC		Ш
	AH	EP 0 965 578	12-22-1999	Suntory Limited		
	Al	EP 1 062 873	12-27-2000	N.V. Nutricia		
	AJ	EP 1 252 824	10-30-2002	Abbott Laboratories		

Signature /Jenna Watts/ Considered 06/10/2009	Examiner Signature	/Jenna Watts/	Date Considered	06/10/2009
---	-----------------------	---------------	--------------------	------------

"SXAMINESE that if reference considered, whether or not citation is in conformance with MPEP 609. Daw line through citation of not in conformance and not considered include copy of this few with east communication to applicant. "Applicants unique citation designation number (optionals on number (optionals on the prince) of USPTO Patent Documents at west space or MPEP 90 10 4. "Setter Office that issued the document, by the No-letter code (NIPO Standard ST.3)." For Japanese patent documents, the indication of the year of the region of the Engineer must precede the senial number of the patent document to the patent document to the patent of comments of the patent document to the pat

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO of process) an application. Confidentially is governed by 38 U.S. 1.22 and 37 CPR 1.14. This collection is estimated to Dours to complete industing gathering, preparing, and submitting the completed application form to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to officer. U.S. Patent and reademark Office, P.D. Bost. 1450, Alexandris, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission of Proposition of the Confidence of the Confide

PTO/SB/08A (09-06) Approved for use through 03/31/2007, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

MADEM
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Act of 1995, no persons are required	respond to a collection of information unless it contains a valid OMB control number.  Complete if Known				
	Application Number	10/576,240			
N DISCLOSURE	Filing Date	April 28, 2006			
	First Named Inventor	Iris MEIRI-BENDEK			
BY APPLICANT	Art Unit	1761			
heets as necessary)	Examiner Name				
. 17	Attomory Docket Mumber	7640 Y06-056			

Sheet	2	of 7	/	Attomey Docket Number   7640-X	06-056
			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	├	Number-Kind Code <sup>2 (f Answn)</sup> US-	+		- Garan pp.
		US-	<del> </del>		
		US-			
	1	US-			
	1	US-			
		US-			
	ـ	US-			
	├	US-			
	+	US-			
	$\vdash$	US-			
	+-	US.			

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ.
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Or Relevant Figures Appear	To
	AK	WO 00/56869	09-28-2000	Enzymotec LTD.		
<u> </u>	_					L
	├					├-
	1					⊢
L		1		L	L	_

Date Examiner 06/10/2009 /Jenna Watts/ Considered Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include conv. of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of Examinest, make intervience consequentity, without or not colored and consequential and one of the consequential and the properties are provided and the consequential a the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no personal Substitute for form 1449/PTO

PTO/SB/06B (09-06)
Approved for use through 03/13/207. 0MB 0651-061
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
are required to respond to a collection of information unless it contains a valid 0.0MB control number.

MADENAM

	Complete if Known	
Application Number	10/576,240	FEBE
Filing Date	April 28, 2006	(G
First Named Inventor	Iris MEIRI-BENDEK	JAN 1 0 2007
Art Unit	4704	12

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AL	SUSAN E, CARLSON, PH.D. et al., Docosahexaenoic acid status of preterm infants at birth and following feeding with human milk or formula, Arn. J. Clin. Nutr., 1986, pp. 798-804, v. 44, American Society for Clinical Nutri	
	АМ	VIRGILIO P. CARNIELLI, et al., Feeding premature newborn infants palmitic acid in amounts and stereoisomeric position similar to that of human milke effects on fat and mineral balance, Am. J. Clin. Nutr., 1995, pp. 1037-	
	AN	VIRGILIO P. CARNIELLI, et al., Structural Position and Amount of Palmitic Acid in Infant Formulas: Effects on Fat, FatV Acid, and Mineral Balance, Journal of Pediatric Gastroenterology and Nutrition, December 1996, pp. 553-560, v. 23(5).	
	AO	J. E. CHAPPELL, B. A. SC., et al., Fatty acid balance studies in premature infants fed human milk or formula: Effect of calcium supplementation, Fetal and Neonatal Medicine, The Journal of Pediatrics, March 1986, pp. 439-447, v. 108, n. 3.	
	AP	L. J. FILER, JR., et al., Triglyceride Configuration and Fat Absorption by the Human Infant, J. Nutrition, pp. 293-298, v. 99.	
	AQ	MARGIT HAMOSH, Ph. D., Lingual and Gastric Lipases, Nutrition, November/December 1990, pp. 421-428, v. 6, n. 6.	
	AR	FIKRI M. HANNA. M. D., et al., Calcium-Faity Acid Absorption in Term Infants Fed Human Milk and Prepared Formulas Simulating Human Milk, Pediatrics, February 1970, pp. 216-224, v.45, n. 2.	
	AS	OLLE HERNELL, et al., Digestion and Absorption of Human Milk Lipids, Perinatal Nutrition, Academic Press., 1988, pp. 259-272.	
	AT	SHEILA M. INNIS, et al., Plasma and red blood cell fatty acids of low-birth-weight infants fed their mother's expressed breast milk or preterm-infant formula, Am. J. Clin. Nutr., 1990, pp. 994-1000, v. 51, American Society for Clinical Nutrition.	
	AU	SHEILA M. INNIS, PH. D., et al., Effects of Developmental Changes and Early Nutrition on Cholesterol Metabolism in Infancy: A Review, Journal of the American College of Nutrition, 1992, pp. 635-885., v. 11. n. 2.	

|--|

"EXAMMER: Initial if reference considered, whether or not claison is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique claiston designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 3° CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is powered by 50 U.S. C. 122 and 3° CFR 1.1.4 This collection is estimated to take 2 hours benefit, including pathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing fibs budgen, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

$\overline{}$	Substitute for form 1449/PTO				required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
Occounts				Application Number	10/576,240	AR E		
INF	DRMATION	DIS	CLOSURE	Filing Date	April 28, 2006	The rice		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Iris MEIRI-BENDE	K IAN 1 9 2007 W		
	(Use as many she	wte ae e	occessed.	Art Unit	1761	3		
	(Use as many sine	7612 d2 f1	ecessary)	Examiner Name		BY DANEMAN		
Sheet	4	of	7	Attorney Docket Number	7640-X06-056			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AV	SHEILA M. INNIS, et al., Saturated fatty acid chain length and positional distribution in infant formula: effects on growth and plasma lipids and ketones in piglets, Am. J. Clin. Nutr., 1993, pp. 382-390, v. 57, American Society for Clinical Nutrition.	
	AW	SHEILA M. INNIS, et al., Evidence That Palmitic Acid Is Absorbed as sn-2 Monoacylglycerol from Human Milk by Breast-Fed Infants, 1994, Lipids, pp. 541-545, v. 29, n. 8.	
	AX	SHEILA M. INNIS, et al., Palmitic Acid Is Absorbed as sn-2 Monopalmitin from Milk and Formula with Rearranged Triacylglycerols and Results in Increased Plasma Triglyceride sn-2 and Cholesteryl Ester Palmitate in Piglets, Nutrient Metabolism, J. Nutr., 1995, pp. 73-81, v. 125, American Institute of Nutrifion.	
	AY	CHRISTINE JENSEN, MS, RD, et al., Absorption of individual fatty acids from long chain or medium chain triglycerides in very small infants, The American Journal of Clinical Nutrition, May 1986, pp. 745-751, v. 43, American Society for Clinical Nutrition	
	AZ	B. KOLETZKO, et al., Effects of dietary long-chain polyunsaturated fatty acids on the essential fatty acid status of premature infants, European Journal of Pediatrics, 1989, pp. 669-675, v. 148.	
	ВА	ERIC L. LIEN, et al., The Effect of Triglyceride Positional Distribution on Fatty Acid Absorption in Rats, Journal of Pediatric Gastroenterology and Nutrition, August 1997, pp. 167-174, v. 25(2).	
*	вв	A. LOPEZ-LOPEZ, et al., The influence of dietary palmitic acid triacy/glyceride position on the fatty acid, calcium and magnesium contents of at term newborn faecas, Early Human Development, 2001, pp. S83-S94, v. 65 Suppl., www.eslewirc.com/locate/arthundev.	
	вс	A. LUCAS, et al., Randomised controlled trial of a synthetic triglyceride milk formula for preterm infants, Original Articles, Archives of Diseases in Childhood, 1997, pp. F178-F184, v.77.	
	BD	F. H. MATTSON, et al., The Specificity of Pancreatic Lipase for the Primary Hydroxyl Groups of Glycerides, J. Biol. Chem., pp. 735-740, v. 219, 1956.	
	BE	STEVEN E. NELSON, et al., Palm olein in infant formula: absorption of fat and minerals by normal infants, Am. J. Clin. Nutri., 1996, pp. 291-296, v. 64, American Society for Clinical Nutrition.	

Examiner	/Jenna Watts/	Date	06/10/2009
Signature	Toomia Trailo	Considered	00/10/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Indomation is required by 3° CFR 1.38. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 3° US.C. 12 and 3° UFR 1.14. This collection is estimated to back 2 hours to complete, including approximately an approximately to generate vg 30 00.00. Let all at 0 or 1.11. In a december to settlement or against a property of the settlement of the of the s Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons at Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
333332 33 3311 14431 15	Application Number	10/576,240	
INFORMATION DISCLOSURE	Filing Date	April 28, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Iris MEIRI-BENDEK	
(Use as many sheets as necessary)	Art Unit	1761 JAN 9	
para at many and at material and	Examiner Name	MAT A TRACE	
Sheet 5 of 7	Attorney Docket Number	7640-X06-056	

		NON PATENT LITERATURE DOCUMENTS	
		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ilem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BF	STEVEN E. NELSON, BA, et al., Absorption of Fat and Calcium by Infants Fed a Milk-Based Formula Containing Palm Olein, Journal of the American College of Nutrition, 1998, pp. 327-332, v. 17, n. 4.	
	BG	KARIN M. OSTROM, PH. D., et al., Lower Calcium Absorption in Infants Fed Casein Hydrolysate- and Soy Protein-Based Infant Formulas Containing Palm Clein Versus Formulas without Palm Clein, Journal of the American College of Nutrition, 2002, pp. 584-599, v.2.1 n. 6.	
	вн	JANE C. PUTMAN, M. S., et al., The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants, The American Journal of Clinic	
	Ві	P. T. QUINLAN, et al., The Relationship between Stool Hardness and Stool Composition in Breast- and Formula-Fed Infants, Journal of Pediatric Gastroenterology and Nutrition, 1995, pp. 81-90, v. 20.	
	ВЈ	DONALD M. SMALL, The Effects of Glyceride Structure on Absorption and Metabolism, Annual Rev. Nutr., 1991, pp. 413-434, v. 11.	
-	ВК	R. M. TOMARELLI, et al., Effect of Positional Distribution on the Absorption of the Fatty Acids of Human Milk and Infant Formulas, J. Nutrition, 1968, pp. 583-590, v. 95.	
	BL	J. P. VAN BIERVLIET, et al., Plasma Apoprotein and Lipid Patterns in Newborns: Influence of Nutritional Factors, Acta Paediatr. Scand., 1981, pp. 851-856, v. 70.	
	вм	CHI-SUN WANG, et al., Studies on the Substrate Specificity of Purified Human Milk Bile Salt- activated Lipase, The Journal of Biological Chemistry, 10 August 1983, pp. 9197-9202, v. 258, n.15.	
	BN	ELSIE M. WIDDOWSON, et al., Body Fat of British and Dutch Infants, British Medical Journal, 22 March 1975, pp. 653-655, v.1.	
	во	Database Medline/NLM Online, 15 November 1997, Cadogan J. et al., "Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial", XP002315046, database access no. NLM9390050, British Medical Journal, v. 315, pp. 1255-1280.	

Examiner	/Jenna Watts/	Date	06/10/2009
Signature	/Jenna Watts/	Considered	00/10/2009

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Agriciant's unique clatero resignation number (optional). 2 Agriciant is to place a check mark here if Engish language Translation is attached.
This solication of information is required by 37 CFR 1.87. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons an Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substitute for form 14437 To	Application Number	10/576,240	
INFORMATION DISCLOSURE	Filing Date	April 28, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Iris MEIRI-BENDEK	
(Use as many sheets as necessary)	Art Unit	1761 JAN 1 0 E	
lose as many sheets as necessary	Examiner Name	The same	
Sheet 6 of 7	Attorney Docket Number	7640-X06-056	

		NON PATENT LITERATURE DOCUMENTS	
Examiner   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue	T <sup>2</sup>
	BP	Database Medline/NLM Online, USNLM, XP002315047, database access no. NLM14520257, October 2003, Volek, Jeff S. et al.: "Increasing fluid milk favorably affects bone mineral density responses resistance training in adoles	
	BQ	Database Embase/Elsevier Orline, Elsevier Science Pub., XP002315048, database access no. EMB- 200038954, 2000, Gueguen L.: "Calcium balance: Requirenments, intake and bloavallability", Nutrition Clinique at Metabolisms.	
	BR	Database Embase/Elsevier Online, Elservier Science Pub., XP002315049, Database access no. EMB- 200330690, 1 September 2003, 36bbc-Ahrens K.E.: "Nutrients of milk and their relevance for health", Medizinische Welt, v. 54, n. 9, pp. 222-230.	
	BS	Database FSTA/IFIS Online, XP002315600, Database access no. 96-1-08-n0030, World of Ingredients, March/April 1996, Anonymous: "Betapol, a breakthrough in infant formula fats".	
	вт	"Enzymotec launches InFat-perfect fat for infant formulas", Online, 4 July 2003, XP002315599, Retrieved from Internet URL: www.foodingredientsfirst.com/newsmaker.	
	BU	Database Blosls Online, Biosciences Info. Service, XP002315050, Database access no. PREV199799383168, 1996, Carrielli Virgilio P. et al. "Structural position and amount of palmitte cald in infant formulas: Effects on fat, fatty acid, and mineral balance", J. of Ped. Gastro. 8 Nutrilion. v. 23, n. 5, pp. 555-505.	
	BV	Database FSTA/IFIS Online, XP002315051, Database access no. 2000-00-g0249, FSTA, 1999, Kennedy K. et al.: "Double-blind, randomized trial of a synthetic tricy(glycerol in formula-fed term infants: effects on stool biochemistry, stool characteristics, and bone miteralization", Am. J. of Clinical Nutrition, v. 70(5), pp. 920-927.	
	BW	Database Embase/Elsevier Online, Elsevier Science Pub., XP002315052, Database access no. EMB-1979225226, Jenness R.: "The composition of human milk", Seminars in Perinatology, 1979.	
	вх	Database Medline/NLM, USNLM, XP002315783, access no. NLM9462186, November 1997, Lucas A et al.: "Randomised controlled trial of a synthetic triglyceride milk formula for preterm infants", Archives of Disease in Childhood, Fetal and Noonatel edition, v. 77, n. 3, pp. F178-F184.	
	BY	R. JACOBSEN, et al., Effect of short-term high dietary calcium intake on 24-h energy expenditure, fat oxidation, and fecal fat excretion, international Journal of Obesity, 2005, pp. 292-301, v. 29.	

Examiner Signature	/Jenna Watts/	Date Considered	06/10/2009		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not					

considered. Include copy of this form with next communication to applicant.

Applicant is uniformation or time some wan reaccumentation to approxime.

Applicant is uniformation cultation designation number (goldonia). Applicant is not place a check much teem if Equido Imprigation and the control of the cont Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/576.240 INFORMATION DISCLOSURE Filing Date April 28, 2006 STATEMENT BY APPLICANT First Named Inventor Iris MEIRI-BENDE Art Unit AN 1 9 2007 1761 (Use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet 17 7 of 7640-X06-056

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>	
	BZ	ROBERT G. JENSEN, Invited Review: The Composition of Bovine Milk Lipids: January 1995 to December 2000, J. Dairy Sci., pp. 295-350, v. 85.	
	CA	http://www.umm.edu/home>medical reference>alternative/ complementarymedicine>Tabledcontents>depletions>AntocidsAluminumCalciumandMagnediumContainingPre parationsch.lmt, Univ. of Marytand Medical Center Website.	
		-	

Signature	/Jenna walls/	Considered	06/10/2009
*EVAMINED: I	itial if reference considered whether or not citation is in conformance with MDED 600	O Denve line through o	itation if not in conformance and not

exhausters: Initial interested considered, whether or not disabol is in combination with any considered, include copy of this form with next communication to applicant.

/ Jonna Matte/

Examiner

Date

0014010000

<sup>1</sup> Applicant's unique clistion designation number (optional). 2 Applicant is to piece a chack mark here if English Ingruige Translation is attached. This collection of information is required by 37 CFR.19. The information is required to obtain or retain a benefit by the public which is to fine (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.11. This collection is estimated to take 2 nours to complete, including againsting, preparing, and submitting the completed application from to the USPTO. This will knowly depending up the 2 nours of the Complete application from the USPTO. This will knowly depending up the Complete application from the USPTO. This will knowly depending up the Complete application from the USPTO. This will knowly depending up the Complete application from the USPTO. This will knowly depending up the Complete application from the USPTO. This will knowly depending up the Complete application from the USPTO. The Complete application from the USPTO. The USP